Over the course of two epidemic seasons , the vaccine efficacy was 97.4 % ( 95 % confidence interval [ CI ] , 92.9 to 99.0 ) according to the intention-to-treat analysis and 97.3 % ( 95 % CI , 92.6 to 99.0 ) according to the per-protocol analysis .